Correspondence 0001683168-25-000288 from Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: Jan. 13, 2025 · CIK: 0001402328 · Accession: 0001683168-25-000288
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284142
Letter
Sunshine Biopharma Inc.
333 Las Olas Way
CU4 Suite 433
Fort Lauderdale, FL 33301
January 13, 2025
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma Inc.
Registration Statement on Form S-3
Filed January 6, 2025
File No. 333-284142
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, January 15, 2025, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma Inc.
Show Raw Text
CORRESP
1
filename1.htm
Sunshine Biopharma Inc.
333 Las Olas Way
CU4 Suite 433
Fort Lauderdale, FL 33301
January 13, 2025
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma Inc.
Registration Statement on Form S-3
Filed January 6, 2025
File No. 333-284142
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated
under the Securities Act of 1933, as amended, Sunshine Biopharma Inc. hereby respectfully requests acceleration of the effectiveness of
the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, January
15, 2025, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma Inc.
By: /s/ Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chief Executive Officer